Epilepsy-Focused Bright Minds Biosciences A High-Risk, High-Reward Play, Analyst Initiates With Over 150% Stock Upside

Why did a judge halt Trump’s federal layoffs? What is behind the US-China trade talks in Geneva? How will Google’s $1.4 billion privacy settlement affect business? Why did Tesla fire employee critical of Elon Musk? What impact did India-Pakistan ceasefire have on markets? How are Trump’s tariffs affecting US consumer prices? Why is Apple fighting over its $20 billion commission? What caused the temporary pause on Trump’s mass firings? How is Warren Buffett preparing Berkshire Hathaway retirement?

Epilepsy-Focused Bright Minds Biosciences A High-Risk, High-Reward Play, Analyst Initiates With Over 150% Stock Upside

benzinga.com/general/biotech/25/05/45268347/epilepsy-focused-bright-minds-biosciences-a-high-risk-high-reward-play-analyst-initiates-with-ove

Chardan Research initiated coverage on Wednesday of Bright Minds Biosciences Inc. (NASDAQ:DRUG), an epilepsy drug developer.
The company’s lead product, BMB-101, is a novel scaffold 5-HT2C Gq-protein biased agonist developed using structure-based drug design.
The drug candidate is…

This story appeared on benzinga.com, 2025-05-07 20:45:18.